Clinigen Group (LON:CLIN)‘s stock had its “buy” rating restated by stock analysts at Peel Hunt in a research note issued to investors on Wednesday, June 26th, Digital Look reports. They presently have a GBX 1,390 ($18.16) target price on the stock. Peel Hunt’s price target suggests a potential upside of 46.39% from the company’s previous close.
Several other research firms also recently weighed in on CLIN. Numis Securities reiterated a “hold” rating and set a GBX 1,500 ($19.60) price objective on shares of Weir Group in a research report on Wednesday, February 27th. Royal Bank of Canada reiterated a “hold” rating and set a $3.00 price objective on shares of Frontier Communications in a research report on Wednesday, February 27th. Four research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Clinigen Group currently has an average rating of “Buy” and a consensus target price of GBX 1,371 ($17.91).
Clinigen Group stock traded down GBX 10.50 ($0.14) during midday trading on Wednesday, reaching GBX 949.50 ($12.41). The company’s stock had a trading volume of 175,650 shares, compared to its average volume of 432,646. The stock’s 50-day simple moving average is GBX 1,007.55. The company has a debt-to-equity ratio of 56.71, a current ratio of 1.54 and a quick ratio of 1.32. Clinigen Group has a 52-week low of GBX 716 ($9.36) and a 52-week high of GBX 1,069 ($13.97). The firm has a market capitalization of $1.26 billion and a PE ratio of 47.71.
Clinigen Group plc operates as a specialty pharmaceutical and services company. The company operates through three segments: Commercial Medicines, Unlicensed Medicines, and Clinical Trial Services. The Commercial Medicines segment acquires and licenses commercial medicines and then revitalises them, as well as provides access to licensed and branded generic medicines in the Africa and Asia Pacific region.
Receive News & Ratings for Clinigen Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clinigen Group and related companies with MarketBeat.com's FREE daily email newsletter.